# Elucidating the mechanisms of myomaker function during myoblast fusion

> **NIH NIH F32** · CINCINNATI CHILDRENS HOSP MED CTR · 2021 · $46,599

## Abstract

Project Summary/Abstract
 Myoblast fusion is a fundamental process for proper skeletal muscle formation during development,
regeneration, and exercise-induced adaptivity. In spite of the large number of studies on myoblast fusion, the
molecular mechanisms that govern this highly-coordinated process have remained poorly understood.
Elucidation of the molecular pathways that control fusion is a critical step for understanding muscle develop and
to establish new therapeutic strategies to augment degenerative skeletal muscle diseases. We have recently
provided new insights into the molecular control of myoblast fusion through the discovery of two muscle-specific
membrane proteins (myomaker and myomerger). Both proteins are essential for myoblast fusion and normal
muscle development and regeneration. Furthermore, co-expression of myomaker and myomerger induces
fusion of non-fusogenic fibroblasts, establishing that these fusogens are both necessary and sufficient for fusion
in mammalian cells. More recently, we have shown that myomaker and myomerger drive myoblast fusion by
independently impacting distinct phases of membrane fusion. Within this unique mechanism, myomaker is
required for initial mixing of the outer lipid leaflets (hemifusion) and myomerger completes the fusion reaction
through generation of a fusion pore. While the facilitation of fusion pore formation has been attributed to the
membrane permeabilization activity of myomerger, the mechanistic function of myomaker leading to membrane
remodeling during hemifusion has remained elusive. The main goal of this proposal is to understand the
mechanisms by which myomaker controls myoblast hemifusion, which will eventually be used to design
strategies for cell-based therapies for muscle repair and degenerative disease. We will define the membrane-
remodeling activities of myomaker during myoblast fusion by first testing whether myomaker functions in cis or
in trans using co-immunoprecipitation of affinity-tagged myomaker. We will use an arsenal of fluorescent
membrane dyes as well as FRAP analysis to measure membrane fluidity in myomaker-null and myomaker-
overexpressing cells, and assess lipid content using large-scale lipidomics. Using mutagenesis, we will examine
the roles of several distinct myomaker domains for membrane-remodeling and myomaker localization. To identify
additional factors required for myoblast fusion, we will conduct immunoprecipitation studies of FLAG-tagged
myomaker during myoblast fusion to assess direct binding partners through mass spectrometry. Furthermore,
we will interrogate multiple candidates identified from our genome-wide loss-of-function screen through
CRISPR/Cas9-mediated knockout analyses, and direct interactions with myomaker will be tested. Completion of
these studies will lead to an understanding of the molecular function of myomaker during lipid mixing, as well as
the identification and characterization of the ancillary factors that cooperate with myomaker ...

## Key facts

- **NIH application ID:** 10151293
- **Project number:** 1F32AR077396-01A1
- **Recipient organization:** CINCINNATI CHILDRENS HOSP MED CTR
- **Principal Investigator:** John T. Olthoff
- **Activity code:** F32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $46,599
- **Award type:** 1
- **Project period:** 2021-02-01 → 2021-09-24

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10151293

## Citation

> US National Institutes of Health, RePORTER application 10151293, Elucidating the mechanisms of myomaker function during myoblast fusion (1F32AR077396-01A1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10151293. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
